Last reviewed · How we verify
RRx-001 + eLOOP Device
RRx-001 is a small-molecule immunotherapeutic that works synergistically with the eLOOP device to enhance immune activation and tumor cell death through modulation of immune checkpoints and metabolic pathways.
RRx-001 is a small-molecule immunotherapeutic that works synergistically with the eLOOP device to enhance immune activation and tumor cell death through modulation of immune checkpoints and metabolic pathways. Used for Advanced solid tumors (Phase 3 development), Potentially checkpoint inhibitor-resistant cancers.
At a glance
| Generic name | RRx-001 + eLOOP Device |
|---|---|
| Sponsor | EpicentRx, Inc. |
| Drug class | Immunotherapeutic small molecule |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
RRx-001 is designed to act as an immunogenic cell death inducer and immune checkpoint modulator that enhances anti-tumor immunity. The eLOOP device is a proprietary delivery/activation platform that optimizes RRx-001's bioavailability and therapeutic effect. Together, they aim to overcome resistance to standard immunotherapies by priming the tumor microenvironment and enhancing T-cell infiltration and activation.
Approved indications
- Advanced solid tumors (Phase 3 development)
- Potentially checkpoint inhibitor-resistant cancers
Common side effects
- Fatigue
- Nausea
- Immune-related adverse events
Key clinical trials
- A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer (PHASE3)
- RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RRx-001 + eLOOP Device CI brief — competitive landscape report
- RRx-001 + eLOOP Device updates RSS · CI watch RSS
- EpicentRx, Inc. portfolio CI